Copyright© Jiangsu Rongtai Biotech Co., Ltd. 苏ICP备16058031号 Powered by:300.cn


:

Druggability Evaluation

Matrix metalloproteinase inhibitor polypeptide and its application

 

The present invention relates to the field of medicine, in particular to an angiogenesis inhibitor having inhibition of matrix metalloproteinase and inhibition of migration of vascular endothelial cells, and can be used for the prevention and treatment of solid tumors and rheumatoid arthritis. The polypeptide specifically refers to polypeptide I, polypeptide II, polypeptide III and polypeptide IV (see SeqNO.1, SeqNO.2, SeqNO.3, SeqNO.4); the polypeptide can be used for treating solid tumors and rheumatoid joints inflammation. The use of the four angiogenesis inhibitors in the preparation of therapeutic drugs for tumors is characterized in that the tumors originate from human head and neck, brain, thyroid, esophagus, pancreas, lungs, liver, stomach, breast, kidneys Primary or secondary cancers, melanomas, hemangiomas, and sarcomas of gallbladder, gallbladder, colon, or rectum, ovary, cervix, uterus, prostate, bladder, and testis.